Tivozanib hydrochloride hydrate
Cat. No.: IBDI-436278
Tivozanib hydrochloride hydrate is a selective and orally active VEGFR tyrosine kinase inhibitor with IC50 of 0.21, 0.16, 0.24 nM for VEGFR-1, VEGFR-2, VEGFR-3, respectively. Tivozanib hydrochloride hydrate inhibits angiogenesis and vascular permeability in tumor tissues and shows antitumor activity. Tivozanib hydrochloride hydrate has the potential for the research of metastatic renal cell carcinoma (RCC).
Product Details
| Target |
VEGFR |
| Molecular Weight |
509.34 |
| Appearance |
Solid |
| Synonyms |
AV-951 hydrochloride hydrate, KRN951 hydrochloride hydrate |
| Purity |
99.88% |
Storage & Handling
| Shipping |
Room temperature in continental US. May vary elsewhere. |
| Storage |
Please store the product under the recommended conditions in the Certificate of Analysis. |
| Regulatory Status |
This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. |
! For research use only, not intended for any clinical use.
